Antiviral Drug Resistance: Clinical Consequences and Molecular Aspects

 

 Buy Article Permissions and Reprints

ABSTRACT

Antiviral drug resistance now poses a major problem for the management of patients with chronic hepatitis B. In theory, resistance may be prevented if a sufficiently potent antiviral drug, or combination of antiviral agents, is used that prevents viral replication and thereby the ongoing selection of hepatitis B virus quasispecies. Emergence of drug resistance in patients with hepatitis B generally results in progression of liver disease and in some cases, significant clinical deterioration if hepatic reserve is compromised. Currently, there are two major patterns of resistance mutations found in the viral reverse transcriptase (rt) that can be selected during monotherapy: (1) those that include the codon rtM204, which is part of the catalytic domain (YMDD) of the enzyme; (2) and those that do not include the codon. The rtM204I/V is selected by lamivudine and l-nucleosides. It is also part of the entecavir resistance profile and the tenofovir-lamivudine combination resistance profile. In contrast, resistance to adefovir is associated with mutations at rtN236T ± rtA181V. A reasonable clinical goal is to develop an overall strategy that prevents the selection of resistance. These strategies have yet to be optimized for hepatitis B, but may include multiple therapies such as immune-based therapies in combination with one or more nucleoside analogue treatments. Future treatment protocols can be modeled on the use of multiple agents comprising highly active anti-retroviral therapy regimens that have been developed for the successful management of patients infected with human immunodeficiency virus.

REFERENCES

• 1 Durantel S, Werle B, Durantel D et al.. Different profiles of response to adefovir dipivoxial and factors that may influence response in patients with chronic hepatitis B.  Hepatology. 2004;  40(suppl 1) 654A
  PubMedGoogle Scholar
• 2 Locarnini S, Hatzakis A, Heathcote J et al.. Management of antiviral resistance in patients with chronic hepatitis B.  Antivir Ther. 2004;  9 679-693
  PubMedGoogle Scholar
• 3 Bowden S. Serological and molecular diagnosis.  Semin Liver Dis. 2006;  26 97-103
  Article in Thieme ConnectPubMedGoogle Scholar
• 4 Chu C M, Liaw Y F. Hepatitis B virus-related cirrhosis: natural history and treatment.  Semin Liver Dis. 2006;  26 142-152
  Article in Thieme ConnectPubMedGoogle Scholar
• 5 Zoulim F. In vitro models for studying hepatitis B virus drug resistance.  Semin Liver Dis. 2006;  26 171-180
  Article in Thieme ConnectPubMedGoogle Scholar
• 6 Angus P, Vaughan R, Xiong S et al.. Resistance to adefovir dipivoxil therapy associated with development of a novel mutation in the HBV polymerase.  Gastroenterology. 2003;  125 292-297
  CrossrefPubMedGoogle Scholar
• 7 Tenney D J, Levine S M, Rose R E et al.. Clinical emergence of entecavir-resistant hepatitis B virus requires additional substitutions in virus already resistant to lamivudine.  Antimicrob Agents Chemother. 2004;  48 3498-3507
  CrossrefPubMedGoogle Scholar
• 8 Chin R, Shaw T, Torresi J et al.. In vitro susceptibilities of wild-type or drug-resistant hepatitis B virus to (-)-beta-D-2,6-diaminopurine dioxolane and 2′-fluoro-5-methyl-beta-L-arabinofuranosyluracil.  Antimicrob Agents Chemother. 2001;  45 2495-2501
  CrossrefPubMedGoogle Scholar
• 9 Delaney IV W E, Locarnini S, Shaw T. Resistance of hepatitis B virus to antiviral drugs: current aspects and directions for future investigation.  Antivir Chem Chemother. 2001;  12 1-35
  PubMedGoogle Scholar
• 10 Ono-Nita S K, Kato N, Shiratori Y, Carrilho F J, Omata M. Novel nucleoside analogue MCC-478 (LY582563) is effective against wild-type or lamivudine-resistant hepatitis B virus.  Antimicrob Agents Chemother. 2002;  46 2602-2605
  CrossrefPubMedGoogle Scholar
• 11 Levine S, Hernandez D, Yamanaka G et al.. Efficacies of entecavir against lamivudine-resistant hepatitis B virus replication and recombinant polymerases in vitro.  Antimicrob Agents Chemother. 2002;  46 2525-2532
  CrossrefPubMedGoogle Scholar
• 12 Harrison T J. Hepatitis B virus: molecular virology and common mutants.  Semin Liver Dis. 2006;  26 87-96
  Article in Thieme ConnectPubMedGoogle Scholar
• 13 Locarnini S, Mason W S. Cellular and virological mechanisms of HBV drug resistance.  J Hepatol. 2006;  44 422-431
  CrossrefPubMedGoogle Scholar
• 14 Bartholomeusz A, Tehan B G, Chalmers D K. Comparisons of the HBV and HIV polymerase, and antiviral resistance mutations.  Antivir Ther. 2004;  9 149-160
  PubMedGoogle Scholar
• 15 Bartholomew M M, Jansen R W, Jeffers L J et al.. Hepatitis B virus resistance to lamivudine given for recurrent infection after orthotopic liver transplantation.  Lancet. 1997;  349 20-22
  CrossrefPubMedGoogle Scholar
• 16 Allen M I, Deslauriers M, Andrews C W et al.. Identification and characterisation of mutations in hepatitis B virus resistant to lamivudine. Lamivudine Clinical Investigation Group.  Hepatology. 1998;  27 1670-1677
  CrossrefPubMedGoogle Scholar
• 17 Xiong X, Yang H, Westland C E, Zou R, Gibbs C S. In vitro evaluation of hepatitis B virus polymerase mutations associated with famciclovir resistance.  Hepatology. 2000;  31 219-224
  CrossrefPubMedGoogle Scholar
• 18 Delaney IV W E, Yang H, Westland C E et al.. The hepatitis B virus polymerase mutation rtV173L is selected during lamivudine therapy and enhances viral replication in vitro.  J Virol. 2003;  77 11833-11841
  CrossrefPubMedGoogle Scholar
• 19 Ogata N, Fujii K, Takigawa S, Nomoto M, Ichida T, Asakura H. Novel patterns of amino acid mutations in the hepatitis B virus polymerase in association with resistance to lamivudine therapy in Japanese patients with chronic hepatitis B.  J Med Virol. 1999;  59 270-276
  CrossrefPubMedGoogle Scholar
• 20 Yeh C T, Chien R N, Chu C M, Liaw Y F. Clearance of the original hepatitis B virus YMDD-motif mutants with emergence of distinct lamivudine-resistant mutants during prolonged lamivudine therapy.  Hepatology. 2000;  31 1318-1326
  CrossrefPubMedGoogle Scholar
• 21 Locarnini S, Shaw T, Sozzi T et al.. HBV mutants associated with clinical resistance to adefovir dipivoxil display only small decreases in antiviral sensitivity in vitro.  Hepatology. 2004;  40(suppl 1) 244A
  PubMedGoogle Scholar
• 22 Sheldon J, Camino N, Rodes B et al.. Selection of hepatitis B virus polymerase mutations in HIV-coinfected patients treated with tenofovir.  Antivir Ther. 2005;  10 727-734
  PubMedGoogle Scholar
• 23 Feld J J, Heathcote E J. Hepatitis B e antigen-positive chronic hepatitis B: natural history and treatment.  Semin Liver Dis.  2006;  26 116-129
  Article in Thieme ConnectPubMedGoogle Scholar
• 24 Hadziyannis S J, Papatheodoridis G V. Hepatitis B e antigen-negative chronic hepatitis B: natural history and treatment.  Semin Liver Dis. 2006;  26 130-141
  Article in Thieme ConnectPubMedGoogle Scholar
• 25 Leung N W, Lai C L, Chang T T et al.. Extended lamivudine treatment in patients with chronic hepatitis B enhances hepatitis B e antigen seroconversion rates: results after 3 years of therapy.  Hepatology. 2001;  33 1527-1532
  CrossrefPubMedGoogle Scholar
• 26 Papatheodoridis G V, Dimou E, Laras A, Papadimitropoulos V, Hadziyannis S J. Course of virologic breakthroughs under long-term lamivudine in HBeAg-negative precore mutant HBV liver disease.  Hepatology. 2002;  36 219-226
  CrossrefPubMedGoogle Scholar
• 27 Liaw Y F, Chien R N, Yeh C T, Tsai S L, Chu C M. Acute exacerbation and hepatitis B virus clearance after emergence of YMDD motif mutation during lamivudine therapy.  Hepatology. 1999;  30 567-572
  CrossrefPubMedGoogle Scholar
• 28 Lok A S, Lai C L, Leung N et al.. Long-term safety of lamivudine treatment in patients with chronic hepatitis B.  Gastroenterology. 2003;  125 1714-1722
  CrossrefPubMedGoogle Scholar
• 29 Dienstag J L, Goldin R D, Heathcote E J et al.. Histological outcome during long-term lamivudine therapy.  Gastroenterology. 2003;  124 105-117
  CrossrefPubMedGoogle Scholar
• 30 Lin C L, Tsai S L, Lee T H, Chien R N, Liao S K, Liaw Y F. High frequency of functional anti-YMDD and -mutant cytotoxic T lymphocytes after in vitro expansion correlates with successful response to lamivudine therapy for chronic hepatitis B.  Gut. 2005;  54 152-161
  CrossrefPubMedGoogle Scholar
• 31 Liaw Y F, Sung J J, Chow W C et al.. Lamivudine for patients with chronic hepatitis B and advanced liver disease.  N Engl J Med. 2004;  351 1521-1531
  CrossrefPubMedGoogle Scholar
• 32 Fung S K, Andreone P, Han S H et al.. Adefovir-resistant hepatitis B can be associated with viral rebound and hepatic decompensation.  J Hepatol. 2005;  43 937-943
  CrossrefPubMedGoogle Scholar
• 33 Ayres A, Bartholomeusz A, Lau G, Lam K C, Lee J Y, Locarnini S. Lamivudine and famciclovir resistant hepatitis B virus associated with fatal hepatic failure.  J Clin Virol. 2003;  27 111-116
  CrossrefPubMedGoogle Scholar
• 34 Heathcote J. Treatment of HBe antigen-positive chronic hepatitis B.  Semin Liver Dis. 2003;  23 69-79
  Article in Thieme ConnectPubMedGoogle Scholar
• 35 Bartholomeusz A, Locarnini S, Ayres A et al.. Mechanistic basis for hepatitis B virus resistance to acyclic nucleoside phosphonate analogues, adefovir and tenofovir.  Hepatology. 2005;  42(suppl 1) 594A
  PubMedGoogle Scholar
• 36 Ono S K, Kato N, Shiratori Y et al.. The polymerase L528M mutation cooperates with nucleotide binding-site mutations, increasing hepatitis B virus replication and drug resistance.  J Clin Invest. 2001;  107 449-455
  PubMedGoogle Scholar
• 37 Bock C T, Tillmann H L, Torresi J et al.. Selection of hepatitis B virus polymerase mutants with enhanced replication by lamivudine treatment after liver transplantation.  Gastroenterology. 2002;  122 264-273
  PubMedGoogle Scholar
• 38 Liaw Y F, Chien R N, Yeh C T. No benefit to continue lamivudine therapy after emergence of YMDD mutations.  Antivir Ther. 2004;  9 257-262
  PubMedGoogle Scholar
• 39 Wong V W, Chan H L, Wong M L, Tam J S, Leung N W. Clinical course after stopping lamivudine in chronic hepatitis B patients with lamivudine-resistant mutants.  Aliment Pharmacol Ther. 2004;  19 323-329
  CrossrefPubMedGoogle Scholar
• 40 Angus P, Locarnini S. Lamivudine-resistant hepatitis B virus and ongoing lamivudine therapy: stop the merry-go-round, it's time to get off!.  Antivir Ther. 2004;  9 145-148
  PubMedGoogle Scholar
• 41 Ono-Nita S K, Kato N, Shiratori Y et al.. Susceptibility of lamivudine-resistant hepatitis B virus to other reverse transcriptase inhibitors.  J Clin Invest. 1999;  103 1635-1640
  PubMedGoogle Scholar
• 42 Perrillo R, Hann H W, Mutimer D et al.. Adefovir dipivoxil added to ongoing lamivudine in chronic hepatitis B with YMDD mutant hepatitis B virus.  Gastroenterology. 2004;  126 81-90
  CrossrefPubMedGoogle Scholar
• 43 Peters M G, Hann H W, Martin P et al.. Adefovir dipivoxil alone or in combination with lamivudine in patients with lamivudine-resistant chronic hepatitis B.  Gastroenterology. 2004;  126 91-101
  CrossrefPubMedGoogle Scholar
• 44 Lee C H, Yeon J E, Hong S P et al.. More frequent and earlier emergence of adefovir (ADV) resistance mutations in lamivudine resistant patients treated with ADV compared to previously reported nucleoside-treatment naive patients.  Hepatology. 2005;  42 593A
  PubMedGoogle Scholar
• 45 Fung S K, Lok A S. Management of hepatitis B patients with antiviral resistance.  Antivir Ther. 2004;  9 1013-1026
  PubMedGoogle Scholar
• 46 Suzuki F, Tsubota A, Akuta N et al.. Interferon for treatment of breakthrough infection with hepatitis B virus mutants developing during long-term lamivudine therapy.  J Gastroenterol. 2002;  37 922-927
  CrossrefPubMedGoogle Scholar
• 47 Danalioglu A, Kaymakoglu S, Cakaloglu Y et al.. Efficacy of alpha interferon therapy for lamivudine resistance in chronic hepatitis B.  Int J Clin Pract. 2004;  58 659-661
  CrossrefPubMedGoogle Scholar

Stephen A LorcaniniM.B.B.S. Ph.D. F.R.C.(Path.) 

Victorian Infectious Diseases Reference Laboratory

10 Wreckyn Street, North Melbourne, Victoria 3051, Australia